CLVS Shares Outstanding History



Below is a table of the CLVS shares outstanding history going back to 11/16/2011:

Date CLVS Shares Outstanding
11/16/201120.77M
3/12/201222.38M
5/7/201226.13M
8/8/201226.14M
11/12/201226.14M
3/11/201326.22M
5/2/201326.27M
8/1/201330.17M
11/1/201330.17M
2/24/201433.90M
5/1/201433.91M
8/1/201433.96M
10/31/201433.96M
2/20/201534.02M
5/1/201534.06M
7/31/201538.21M
10/30/201538.32M
2/19/201638.36M
4/29/201638.39M
7/29/201638.50M
10/28/201638.59M
4/28/201744.77M
7/28/201748.88M
10/27/201749.01M
2/21/201850.57M
5/4/201852.55M
7/27/201852.65M
10/26/201852.71M
2/22/201952.87M
5/3/201953.00M
7/26/201954.66M
11/1/201954.82M
2/15/202073.45M
5/5/202076.90M
7/31/202088.20M
10/30/202088.32M
2/12/2021104.53M
4/30/2021104.56M
7/30/2021118.41M
10/29/2021129.98M
2/22/2022142.24M
4/29/2022143.88M
7/29/2022144.48M
11/4/2022144.96M

Also see: CLVS Market Cap History
CLVS YTD Return
CLVS Historical Shares Outstanding:
+19.37% CAGR
CLVS Historical Shares Outstanding: +19.37% CAGR

Mouse over chart for data details
11/16/2011 ...11/4/2022
Clovis Oncology is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents. Co. markets Rubraca®, which is an oral small molecule inhibitor of poly ADP-ribose polymerase for indications specific to recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer. Co.'s product candidates include: FAP-2286, a peptide-targeted radionuclide therapy and imaging agent targeting fibroblast activation protein; and Lucitanib, an oral potent angiogenesis inhibitor which inhibits vascular endothelial growth factor receptors 1 through 3, platelet-derived growth factor receptors alpha and beta and fibroblast growth factor receptors 1 through 3. We show 44 historical shares outstanding datapoints in our coverage of CLVS's shares outstanding history.

Understanding the changing numbers of CLVS shares outstanding — and comprehending the concept of differing number of shares outstanding in general comparing companies like CLVS versus peers — is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies. Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history. With this page we aim to empower investors researching CLVS by allowing them to research CLVS shares outstanding history as well as any other stock in our coverage universe.
Quotes delayed 20 minutes

Email EnvelopeFree CLVS Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts
10 ETFs With Stocks That Insiders Are Buying
10 ETFs With Most Upside To Analyst Targets
The DividendRank Top 25
Warren Buffett Dividend Stocks
10 Cheap Dividend Stocks Under $10
10 Energy Stocks You Can Buy Cheaper Than Insiders Did
10 Top DividendRank'ed Energy Stocks
The 10 Highest Yielding Preferred Stocks
The 10 Highest Yielding Preferred Stocks
The 15 Most Active Call & Put Options of the S&P 500 Components
Video: Shares Outstanding Importance


If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Clovis Oncology (CLVS) is categorized under the Healthcare sector; to help you further research historical shares outstanding numbers, below are some other companies in the same sector:

CLXT Shares Outstanding History
CMAX Shares Outstanding History
CMD Shares Outstanding History
CMPI Shares Outstanding History
CMPX Shares Outstanding History
CMRA Shares Outstanding History
CMRX Shares Outstanding History
CNAT Shares Outstanding History
CNC Shares Outstanding History
CNCE Shares Outstanding History
More Healthcare companies »

 

CLVS Shares Outstanding History | www.SharesOutstandingHistory.com | Copyright © 2017 - 2024, All Rights Reserved

Nothing in SharesOutstandingHistory.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.
X
Wait! Don't leave yet.
Want to receive our latest research absolutely free?


Click the button below for your complimentary copy of Your Early Retirement Portfolio: Dividends Up to 9.5%—Every Month—Forever.

You'll discover the details on 4 stocks and funds that pay you massive dividends as high as 9.5%.